[6-(5-Benzo[1,3]dioxol-5-yl-1H-imidazol-4-yl)-pyridin-2-yl]-phenylamine | 428816-41-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: [6-(5-Benzo[1,3]dioxol-5-yl-1H-imidazol-4-yl)-pyridin-2-yl]-phenylamine
• 英文别名: 6-[4-(1,3-benzodioxol-5-yl)-1H-imidazol-5-yl]-N-phenylpyridin-2-amine
• CAS: 428816-41-5
• 化学式: C₂₁H₁₆N₄O₂
• 分子量: 356.384
• InChiKey: GVHCSEWZQWUDCU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  72.1
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-(5-Benzo[1,3]dioxol-5-yl-1H-imidazol-4-yl)-6-bromo-pyridine 、 三甲基铝 在 苯胺 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 生成 [6-(5-Benzo[1,3]dioxol-5-yl-1H-imidazol-4-yl)-pyridin-2-yl]-phenylamine
  参考文献：
  名称：

  Compounds

  摘要：

  本发明涉及2-吡啶基取代的二芳基咪唑，它们是转化生长因子（“TGF”）-β信号通路的抑制剂，特别是通过I型或类活素激酶（“ALK”）-5受体对smad2或smad3的磷酸化，它们的制备方法及其在医学上的应用。

  公开号：

  US20040039198A1

文献信息

• COMPOUNDS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP1349851A1

  公开（公告）日：2003-10-08
• EP1349851A4
  申请人：——

  公开号：EP1349851A4

  公开（公告）日：2004-09-08
• [EN] COMPOUNDS<br/>[FR] COMPOSES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2002040468A1

  公开（公告）日：2002-05-23

  2-Pyridyl substituted diarylimidazoles of formula (I) (I)wherein R1 is phenyl or naphthyl optionally substituted with one or more substituents selected from halo, C1-6alkoxy, C1-6alkylthio, C1-6alkyl, C1-6haloalkyl, -O-(CH2)m-Ph, -S-(CH2)m-Ph, cyano, phenyl, and CO2R, wherein R is hydrogen or C1-6alkyl and m is 0-3; or phenyl fused with a 5- to 7-membered aromatic or non-aromatic ring wherein said ring contains up to three heteroatoms, independently selected from N, O and S; R2, R3, R4 and R5 independently represent hydrogen, C1-6alkyl, C1-6alkoxy, C1-6haloalkyl, halo, NH2, NH-C1-6alkyl or NH(CH2)n-Ph wherein n is 0-3; or an adjacent pair of R2, R3, R4 and R5 form a fused 6-membered aromatic ring optionally containing up to 2 nitrogen atoms, said ring being optionally substituted by one or more substituents independently selected from C1-6alkyl, C1-6alkoxy, C1-6haloalkyl, halo, NH2, NH-C1-6alkyl or NH(CH2)n-Ph wherein n is 0-3, and the remainder of R2, R3, R4 and R5 represent hydrogen, C1-6alkyl, C1-6alkoxy, C1-6haloalkyl, halo, NH2, NH-C1-6alkyl or NH(CH2)n-Ph wherein n is 0-3; and one of X1 and X2 is N and the other is NR6, wherein R6 is hydrogen or C1-6alkyland salts and solvates thereof, are disclosed, as are methods for their preparation, pharmaceutical compositions containing them and their use in medicine.